Trillium Therapeutics Inc., a private research and development company, received $12 million from investors to advance in clinical development. Trillium's lead program is constructing an artificial DNA growth factor to be used for the treatment of interstitial cystitis. Looks like there is hope for the future!
Check out the full article at: http://www.newswire.ca/en/releases/archive/September2008/18/c5645.html
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment